ID   FU1-74
AC   CVCL_XA91
SY   FU 1-74
DR   CCRID; 4201PAT-CCTCC00062
DR   JCRB; IFO50185
DR   Wikidata; Q93557388
RX   Patent=US5496549;
RX   Patent=US5506135;
RX   PubMed=1796414;
RX   PubMed=2107601;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2334.
CC   Characteristics: This is a tetradoma, a fusion of two hybridomas.
CC   Monoclonal antibody target: UniProtKB; P02675; Human FGB.
CC   Monoclonal antibody target: UniProtKB; P00749; Human PLAU.
CC   Discontinued: JCRB; IFO50185; probable.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_XA78 ! FIB1-11
HI   CVCL_XA87 ! UK1-3
CA   Hybridoma
DT   Created: 06-09-19; Last updated: 21-03-23; Version: 5
//
RX   Patent=US5496549;
RA   Yamazaki H., Tanoue K., Iwasa S., Kurokawa T.;
RT   "Bispecific monoclonal antibodies, thrombolytic agent
RT   and method of cell lysis.";
RL   Patent number US5496549, 05-Mar-1996.
//
RX   Patent=US5506135;
RA   Iwasa S., Kurokawa T., Toyoda Y.;
RT   "Hybrid monoclonal antibodies, their production and use.";
RL   Patent number US5506135, 09-Apr-1996.
//
RX   PubMed=1796414; DOI=10.1055/s-0038-1646486;
RA   Kurokawa T., Iwasa S., Kakinuma A., Stassen J.-M., Lijnen H.R.,
RA   Collen D.;
RT   "Enhancement of clot lysis in vitro and in vivo with a bispecific
RT   monoclonal antibody directed against human fibrin and against
RT   urokinase-type plasminogen activator.";
RL   Thromb. Haemost. 66:684-693(1991).
//
RX   PubMed=2107601; DOI=10.1016/0049-3848(90)90382-M;
RA   Kurokawa T., Iwasa S., Kakinuma A.;
RT   "Enhancement of fibrinolysis by bispecific monoclonal antibodies
RT   reactive to fibrin and plasminogen activators.";
RL   Thromb. Res. 47 Suppl. 10:83-89(1990).
//